Quarterly ResultMay 14, 2026, 04:28 PM
GeoVax Q1 Net Loss $(5.3)M; Advances GEO-MVA Phase 3 Trial
AI Summary
GeoVax Labs reported a net loss of $5.3 million for Q1 2026, a slight improvement from $5.4 million in Q1 2025, with revenue dropping to zero due to the termination of a BARDA contract. The company highlighted significant progress in its GEO-MVA program, initiating a Phase 3 immunobridging clinical study under an EMA-aligned expedited regulatory pathway. GeoVax also advanced its Gedeptin immuno-oncology platform, securing an exclusive license agreement for combination therapies.
Key Highlights
- Net loss for Q1 2026 was $(5.3) million, compared to $(5.4) million in Q1 2025.
- Revenue for Q1 2026 was $0, down from $1.6 million in Q1 2025 due to contract termination.
- Research and development expenses decreased to $3.9 million from $5.4 million YoY.
- Cash balances were $1.3 million as of March 31, 2026, down from $3.1 million at Dec 31, 2025.
- Initiated Phase 3 immunobridging clinical study for GEO-MVA, expected to enroll approximately 500 participants.
- Completed cGMP clinical trial material and fill/finish product for GEO-MVA clinical use.
- Secured exclusive license agreement with Emory University for Gedeptin in combination with immune checkpoint inhibitors.
- Net loss per common share was $(2.62) for Q1 2026, compared to $(11.20) for Q1 2025.
Price Impact
More from GOVX